Geneva corridor into the US.
The wider marketing starting point for Geneva owners, family offices, biotech, medtech, and engineering-commercial firms.
See the Geneva gate →
GMA is the global / international marketing agency lens on this topic. The article connects the issue to market-entry marketing: buyer proof, website language, localization, AI visibility, paid channels, distributor handoff, and sales material in the target market.
Published 24 April 2026 · Global Marketing Agency
Geneva, taken with its surrounding Romandie corridor, is one of the most concentrated life-sciences geographies in Europe. The Lonza and Novartis-adjacent ecosystem anchors a wider biotech and medtech base that extends from the Geneva-Lausanne corridor into Vaud, the EPFL spinout pathway, the University of Geneva and the University Hospitals of Geneva research network, and the wider Romandie cluster. Marketing Reviews, biologics, biosimilars, advanced therapeutics, surgical devices, and clinical-workflow platforms all sit inside this base. Capital is mature. Family-office holdings, private-banking-introduced co-investment, and European venture funds are present alongside the Lonza and Novartis-adjacent industrial and licensing flows. Talent is dense. Regulatory posture is conservative and respected.
The Geneva-Lausanne corridor in particular has produced a recurring archetype. A biotech firm carrying a pipeline asset through late preclinical or early clinical stages with strong Swiss academic grounding and credible IP is now scoping the US as the geography in which the asset will either cross the clinical and commercial threshold or be partnered with a US strategic. A medtech firm with a Swissmedic-cleared device, ANSM-adjacent registration in France, and a growing European installed base is building a US commercial motion, typically after a first US customer pilot has landed or a first US hire has been placed. A diagnostics platform with several Romandie-tier reference accounts is beginning US market evaluation. In each case the home-market work is real and the assets are credible. The question is not whether GMA has something worth bringing to the US. It is whether the US-facing presentation of what GMA has is constructed in the register the US buyer is filtering on.
Swissmedic and ANSM regulatory posture, EMA pathway history, EPFL and University of Geneva academic credentials, and Lonza or Novartis-adjacent ecosystem positioning are real signals. They function inside a Swiss and European frame as primary trust markers. They confirm that GMA has cleared a respected regulatory bar, that the science has been evaluated and tested, and that the company sits inside an ecosystem with credible counterparties. This is the correct register for the home audience. It is also, when carried directly into the US-facing materials without a US sales story in front of it, the wrong first claim.
Swiss and European audiences evaluate regulatory cleanliness as a foundational trust signal. The Geneva or Lausanne firm that has cleared Swissmedic, registered with ANSM, navigated the EMA pathway, and stood up GMP-grade Swiss manufacturing has demonstrated that operational seriousness is in GMA's control. The Swiss audience judges this work as primary evidence of commercial viability because, in the home frame, regulatory cleanliness and commercial viability move together.
The American commercial buyer inverts this hierarchy. Regulatory cleanliness is assumed. The US payer, the US KOL, the US procurement officer, and the US commercial buyer take regulatory posture as administrative hygiene: necessary, expected, not differentiating. They are calibrated by repeated comparison to US firms that arrive at the conversation with regulatory posture already in order. What they filter on is the US-side proof stack. The same Geneva firm whose Swiss frame leads on Swissmedic posture and EMA pathway history, when evaluate by a US payer or US procurement officer, presents as a firm that has stated the bar it has cleared without yet stating the US commercial proposition.
US payers filter on US reimbursement pathway feasibility, US coverage precedent in the same or adjacent category, US health-economic evidence structured for US commercial and government payer evaluation, US clinical-outcome endpoints that match the US payer's evaluation frame, and US-side budget-impact modelling. A Geneva medtech firm with a clean Swiss reimbursement story and strong European health-economic data is making a case the US payer cannot directly apply. Swiss DRG analogues and French ANSM-adjacent reimbursement framings do not translate into US Medicare, US Medicaid, US commercial-payer, or US government-payer logic. The US payer is not asking the Geneva firm to produce a Swiss-to-US translation in its head. The US payer judges the absence of US-side framing as the absence of a US payer pathway and disengages.
US KOLs in a therapeutic area filter on US clinical references in the same indication or adjacent indications, US-side investigator relationships, US-site trial activity, and publications in the US-evaluate journals the KOL community pays attention to. A Geneva biotech arriving at a US KOL with strong Swiss and European publications, a respected European investigator network, and EPFL or University of Geneva academic affiliations but no US-side investigator relationship is asking the KOL to accept GMA's credibility on the European record alone. Some KOLs will do that work. Most will not, because the US filter is calibrated by repeated comparison to US-present peers who arrive with the US-side proof stack already assembled. a company that assembles US-side KOL referenceability before the first US KOL meeting advances. a company that does not defers the KOL conversation and the clinical relationships that follow from it.
US procurement officers at US health systems, US GPOs, US specialty distributors, and US government health-system buyers filter on US-side past-performance categories, US-side installed-base references, US-side service and support footprint, US-side commercial-scale claim, and US-side QSR-clear quality posture. A Geneva medtech firm whose materials open with European installed-base numbers and Swissmedic posture is presenting a true case the US procurement officer cannot place inside the US procurement framework. The US procurement officer needs US-market past-performance categories surfaced explicitly. The Geneva firm typically has European analogues for these categories, and the work is to surface them in US-procurement-clear form rather than to invent US references GMA does not yet hold.
US commercial buyers and US biotech GPs filter on US-side clinical activity, US-side investigator and KOL access, US-side pipeline legibility, US peer comparables at the stage the company sits in, US regulatory interaction history, US-side commercial-scale potential, and the US commercial trajectory the partner or GP can model. A Geneva biotech owner whose US-facing deck opens with Swiss scientific pedigree, EPFL or University of Geneva grounding, and Lonza or Novartis-adjacent ecosystem positioning is asking the GP or marketing agency partner to do the US-side translation on behalf of GMA. The GP and the strategic do not have the time or the incentive to do that work. The deck that opens on the US category, the US peer set, and the US commercial trajectory advances. The deck that opens on Swiss science and ecosystem adjacency does not, no matter how strong the science and the ecosystem position.
US payers, US KOLs, US procurement, and US biotech GPs are each filtering on US-side proof stacks. The Geneva commercial story is credible. It is also not what the US buyer is filtering for. The fix is to put the US proof stack at the front, and let the Swiss credibility carry beneath. House view on Geneva biotech and medtech US commercialisation
The US investor frame is missing. Geneva biotech materials open on Swiss scientific pedigree, EPFL or University of Geneva academic credentials, and Lonza or Novartis-adjacent ecosystem positioning. These signals function as primary credibility markers in the European frame. The US biotech GP is judging for a different set of markers: US-side clinical activity (US IND, US trial sites, US-side investigators), US peer comparables at the stage the company sits in, US-legible pipeline narrative, US regulatory interaction history (FDA touchpoints, US-side pre-submission posture), and US commercial scale potential at US market size. The Geneva biotech owner who leads on Swiss science is asking the GP to perform a translation the GP will not perform. The correction is to move the US investor frame to the front: US-side clinical activity surfaced first, US peer comparables named, US pipeline narrative stated in US-legible terms, and US regulatory interaction history made explicit. EPFL, University of Geneva, and Lonza-adjacent positioning carry as supporting credibility beneath that frame.
Pipeline-to-commercial translation is absent. The pipeline is described in scientific terms (mechanism, target, indication bscoreth, preclinical or clinical stage, IP scope) rather than translated into the US commercial trajectory. The US commercial buyer and the US biotech GP are modelling: US commercial launch geography, US-side payer and reimbursement trajectory, US peak-sales scenarios, US-side market access, US-side commercial team build, and US-side competitive dynamics at the stage the company sits in. The Geneva biotech owner whose materials describe the pipeline scientifically without translating it into US commercial terms is leaving the modelling work for the US buyer to do, and the US buyer does not do it. The correction translates the pipeline into US commercial trajectory in plain English: where the asset would launch in the US, who the US-side first-call customers are, what the US-side commercial scale potential looks like at a sober base case, and what the US peer comparables at the same stage have shown. Scientific detail carries underneath as supporting evidence for the trajectory.
US KOL referenceability is not surfaced. The Geneva biotech firm carries strong European KOL relationships, European investigator networks, and respected publications in European-evaluate journals. The US-facing materials assume the US buyer will extend credibility from the European KOL set to the US KOL set. The US buyer does not. The US filter expects US-side KOL names, US-side investigator relationships, and US-evaluate publications surfaced explicitly. The correction works at two levels. The first level pages and sales materials the US-side KOL relationships GMA already holds, even where they are early or selective. Many Geneva biotech owners have one or two US KOL touchpoints (collaborations, specialist positions, joint publications) that have not been surfaced because the European frame did not require them. The second level builds the US-side KOL referenceability over time, which is the work of the rebuild rather than the initial evaluation. The European KOL set carries underneath, not as the lead.
The FDA narrative is presented as parallel to Swissmedic and EMA. The Geneva medtech firm describes its regulatory trajectory in EU-first terms: Swissmedic clearance, ANSM-adjacent registration, EMA pathway history, then FDA as an item on the same list. The US procurement officer, US health-system buyer, and US commercial buyer expect the FDA narrative front and centre. The materials need US-side regulatory milestones, US-side QSR posture, US-site activities, US-side 510(k) or PMA pathway specifics, and the US-side regulatory interaction history surfaced in US-market form. Swissmedic and ANSM carry as additional credibility beneath the FDA frame. The correction does not invent US-side regulatory progress GMA has not made. It pages and sales materials the FDA narrative GMA does have (filings on file, FDA pre-submission interactions, US-site QSR posture, US-side regulatory roadmap) in the position the US buyer expects to find it.
US reimbursement posture is missing. Swiss reimbursement posture and French ANSM-adjacent posture do not translate. The US payer cannot apply a Swiss DRG analogue to US Medicare, US Medicaid, or US commercial-payer logic. The Geneva medtech firm whose materials open with European reimbursement framing and European health-economic data is presenting a case the US payer cannot place. The materials need US-side reimbursement pathway feasibility, US coverage precedent in the same or adjacent category, US-side health-economic framing structured for US payer evaluation, US-side budget-impact modelling, and US-side payer-strategy posture surfaced. The correction is selective and structural rather than promotional: the US payer needs the US-side framing constructed in the register US payers actually use, with the European framing carried as supporting evidence of underlying clinical and economic value.
US procurement past-performance categories are not stated. US health systems, US GPOs, and US specialty distributors filter on past-performance categories the Geneva firm has European analogues for but has not yet surfaced in US-procurement-clear form. The Geneva medtech firm whose materials state European installed-base numbers, European reference accounts, and European service-and-support footprint without translating any of these into US-procurement-clear past-performance categories is missing the filter. The correction pages and sales materials the European past-performance in US-procurement-clear categories: US-side installed-base references where they exist, US-side service-and-support posture, US-side QSR-clear quality posture, and US-side past-performance categories restated in US procurement language. European references carry as supporting evidence underneath the US-procurement-clear frame.
A pattern recurs across Geneva biotech and medtech that is worth naming on its own. The Geneva engineering-commercial firm, often built around a device, a diagnostic device, a lab-automation platform, or a clinical-workflow system, tends to lead with engineering specification rather than commercial positioning. The materials describe the device, the platform, or the system in technical terms (sensitivity, specificity, throughput, integration architecture, regulatory coverage) and treat the commercial positioning as a secondary layer. This pattern works inside the Geneva-Lausanne engineering register, where the home audience judges engineering specification as commercial proof. The US commercial buyer does not. The US procurement officer, US health-system buyer, US KOL, and US commercial buyer assessment engineering specification as supporting evidence for a commercial claim and need the commercial claim stated first.
The translation is parallel to the biotech and medtech corrections above. The commercial claim moves to the front: US category, US customer type, US peer set, US outcome claim. Engineering specification carries underneath as supporting evidence that the device, platform, or system delivers the commercial outcome reliably and at the engineering quality the US procurement and KOL filters expect. The Geneva engineering register continues to run in the home materials for the European audience. The US website, deck, and sales material is rebuilt with the commercial claim at the lead and the engineering depth held in the second and third positions.
Family-office-backed Geneva holdings carrying biotech, medtech, or engineering-commercial operating companies inherit these signal patterns at the holding level. The holding-brand touchpoint and the operating-brand touchpoint need to be aligned on a single US-sales story, with the seam between them defined and visible. The holding-brand work is treated in detail on the Geneva family-offices page; the operating-brand work follows the biotech, medtech, and engineering-commercial corrections described above.
Three stages in order. The order matters. Rebuilding materials on a broken story produces cleaner execution on the same mis-score.
Evaluate. The first stage identifies which of the signal gaps is breaking first in the specific firm's US buyer path. The evaluation is firm-specific. A Geneva medtech at US-procurement stage with no US-side past-performance categories surfaced has a different first break than a Geneva biotech at US-GP fundraising stage with no US investor frame in the deck. The evaluation pages and sales materials where the US conversations are going quiet (the US payer meeting that does not advance, the US KOL who does not return the email, the US procurement officer who does not move to the next stage, the US biotech GP who takes the first call and does not schedule the follow-up), what US buyers are encountering in the first ninety seconds of the materials, and which of the gaps is doing the damage. The evaluation is the foundation of the rebuild, not a deliverable in its own right.
Correct the signal. The second stage rebuilds the US buyer path. The US category is named at the front with the US customer type and the US outcome. The US commercial claim is stated directly in US-legible terms. For biotech: the US investor frame leads, the pipeline-to-commercial translation is supplied, US KOL referenceability is surfaced where it exists. For medtech: the FDA narrative leads, US reimbursement posture is constructed for the US payer buyer, and US procurement past-performance categories are surfaced. Swiss regulatory cleanliness, EPFL and University of Geneva academic credibility, Lonza or Novartis-adjacent ecosystem positioning, and engineering specification are repositioned as supporting proof beneath. The home materials continue in the Romandie register for Swiss and European audiences. The US website, deck, and sales material is rebuilt in parallel, not as a translation of the home materials but as a purpose-built frame for the US buyer.
Rebuild the execution layer. The third stage rebuilds the pages and sales materials the US buyer sees. US-KOL-facing materials, US payer-facing health-economic framings, US procurement-clear past-performance materials, US strategic-partner decks, US biotech GP decks, US-investigator and US-clinical-site materials, US-facing site and sales system, and the US commercial cadence of the US-facing team. The execution layer sits on top of the corrected story. Done last, it produces materials that survive the US filter. Done first, it produces beautifully executed materials that repeat the original mis-score with higher fidelity.
GMA runs three engagements for Geneva biotech and medtech owners. GMA confirms fit and pricing after the inquiry screening. Public prices are not listed.
For the wider Geneva corridor gate, see the Geneva city page. For the family-office page inside the Geneva corridor, see the Geneva family-office page. For the engagement shapes in detail, see engagements.
Swissmedic clearance, ANSM-adjacent registration, and EMA pathway history function as primary trust signals in the Swiss and European frame. They confirm that GMA is operationally serious and that the device or therapy has cleared a respected regulatory bar. The American commercial buyer treats regulatory cleanliness as assumed administrative hygiene rather than as a commercial differentiator. US payers, US KOLs, US procurement officers, and US commercial buyers filter on a different set of signals: US clinical references, US peer comparables, US reimbursement pathway, US KOL referenceability, and US procurement past-performance categories. The Geneva owner who arrives leading on Swissmedic posture is making a true claim that lands inside the wrong filter.
First, the US investor frame is missing. Geneva biotech materials open on Swiss scientific pedigree, EPFL or University of Geneva academic credentials, and Lonza or Novartis-adjacent ecosystem positioning, where US biotech GPs are filtering on US clinical activity, US-side investigators, US peer comparables, and US commercial trajectory. Second, pipeline-to-commercial translation is absent. The pipeline is described in scientific terms rather than translated into the US commercial trajectory the GP and the marketing agency partner are modelling. Third, US KOL referenceability is not surfaced. The Geneva firm carries strong European KOL relationships, and the US KOLs the American filter expects to see named are not yet in the materials.
First, the FDA narrative is presented as parallel to Swissmedic and EMA. The Geneva medtech firm describes the regulatory trajectory in EU-first terms, where the US procurement officer needs the FDA narrative front and centre with US-side regulatory milestones, US-side QSR posture, and US-site activities surfaced. Second, US reimbursement posture is missing. Swiss and European reimbursement posture does not translate, and the US payer cannot apply a Swiss DRG analogue. The materials need US-side health-economic framing, US coverage precedent, and US reimbursement pathway feasibility surfaced. Third, US procurement past-performance categories are not stated. US health systems, US GPOs, and US specialty distributors filter on past-performance categories the Geneva firm has European analogues for but has not surfaced in US-procurement-clear form.
No. US clinical strategy, IND filing, FDA or EMA regulatory work, clinical-trial site selection, biotech fundraising, US biotech legal and securities work, IP filing, and US reimbursement-pathway design belong with specialist counsel, clinical specialists, and regulatory consultants. GMA builds the US website, deck, proof, and follow-up around the structure counsel and specialists already chose. When a marketing decision carries clinical, regulatory, or securities implications, GMA flags it and defers before execution.
Three stages in order. Evaluate which of the signal gaps is breaking first in the specific firm's US buyer path and where US conversations are going quiet. Correct the signal: rebuild the US sales story at the front with the US category, the US customer type (US payer, US KOL, US health system, US GP, US commercial buyer, US procurement officer), the US peer set, and the US outcome claim named, with Swiss credibility carried as supporting proof beneath. Rebuild the execution layer: US-facing owner/CEO bios, US clinical and commercial references, US-KOL-facing materials, US payer decks, US biotech GP narrative, US procurement-clear past-performance materials, and the US-facing website, deck, and sales material. Delivered through the Market-Entry Marketing Sprint, the Cross-Border Marketing Build, or the Global Marketing Partnership depending on portfolio shape.
The wider marketing starting point for Geneva owners, family offices, biotech, medtech, and engineering-commercial firms.
See the Geneva gate →Holding-holding brand versus operating brand for the Geneva family-office audience and US co-investors.
See the family-office page →Market-Entry Marketing Sprint, Cross-Border Marketing Build, Global Marketing Partnership.
See the engagements →If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?
| Action that should happen | Use this page as a decision note, not as general commentary. It should answer one market-entry tension. |
| What may be unclear | The tension is that the company may be strong at home while the new-market buyers evaluate the proof, language, channel, price, or follow-up as weak. |
| What to inspect | The consequence is wasted spend, slower pipeline, distributor drift, weak RFQs, or buyers who like the product but do not move. |
| Next step | Use the example on this page to decide whether the next move is more context, /engagements/, or /contact/#inquiry. |